Overview

• Geron Q2 product revenue rises to $49 mln, driven by RYTELO sales

• Net loss narrows sharply to $16.4 mln, operating income beats estimates

• Harout Semerjian appointed as new President and CEO

Outlook

• Geron maintains 2025 operating expenses guidance of $270 mln to $285 mln

• Company expects existing cash and RYTELO sales to fund operations

• Geron plans RYTELO launch in select EU countries in 2026

• IMpactMF trial full enrollment expected by year-end 2025

Result Drivers

• RYTELO SALES - Achieved $49 mln in net product revenue for Q2 2025, a 24% increase from Q1, driven by increased demand from new patient starts

• COMMERCIAL EXPANSION - Expanded sales team by 20% and doubled medical science liaisons to boost RYTELO adoption

• EU LAUNCH PREPARATION - Preparing for RYTELO launch in select EU countries following recent approval

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Geron Corp is $4.00, about 70% above its August 5 closing price of $1.20

Press Release: ID:nBw8Yn88ba

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)